Tesofensine

Plain-English version: tesofensine is an experimental diet pill. It works on brain chemistry rather than gut hormones, raising the levels of three "feel-full / feel-alert" signaling chemicals so you eat less and burn slightly more.

It was originally developed by the Danish company NeuroSearch A/S under the code name NS2330 as a treatment for Parkinson's disease and Alzheimer's disease. Those neurological programs did not pan out — but along the way, researchers noticed that patients were losing weight. That side effect became the whole point, and the compound was redeveloped as an anti-obesity drug (later carried forward by Saniona, largely in a combination product called Tesomet).^[7]

Chemically, tesofensine is a small molecule, not a peptide. It belongs to a class called triple monoamine reuptake inhibitors: it blocks the transporter proteins that normally vacuum serotonin, norepinephrine, and dopamine back out of the synapse (the gap between nerve cells). By slowing that cleanup, it raises the working concentration of all three at once — a broader net than older single- or dual-target diet drugs such as lorcaserin (serotonin only) or phentermine (norepinephrine and dopamine).

The credibility caveat, stated up front: tesofensine is not approved for any use by the U.S. FDA, the European Medicines Agency, or any other major regulator. Real human trials exist — which sets it apart from many "research peptides" — but the largest completed obesity studies are Phase 2, not the big Phase 3 outcome trials that approval requires. You will see claims online of "completed Phase 3 trials in Mexico"; we could not verify any primary source for a Phase 3 obesity result, so this guide does not treat that as established. For the broader legal picture, see Are Peptides Legal?

Takeaway first: tesofensine's weight loss comes mostly from eating less, with a smaller contribution from burning slightly more — and that appetite suppression traces back to boosting three brain chemicals at once. Here is what the verified research actually shows, and where it stops.

The core mechanism: triple monoamine reuptake inhibition

"Monoamines" are a family of signaling molecules that includes serotonin, norepinephrine, and dopamine. After a nerve cell fires, transporter proteins normally pull these chemicals back for reuse. Tesofensine blocks those transporters, so the monoamines linger longer and their signals are amplified. In broad strokes:

• Serotonin (5-HT): reinforces satiety — the "I'm full" signal — which curbs appetite.
• Norepinephrine (NE): raises sympathetic ("fight or flight") tone, which modestly increases energy expenditure and is also the source of the heart-rate signal discussed below.
• Dopamine (DA): modulates the brain's reward system, which may blunt the pleasure-driven pull toward high-calorie food.

What the human data show about mechanism

A mechanistic human study helps separate "eating less" from "burning more." In Sjödin and colleagues, healthy overweight and moderately obese men were given tesofensine (2.0 mg/day for one week, then 1.0 mg/day for a second week). The dominant effect was pronounced appetite suppression, alongside a slight increase in nighttime energy expenditure — both contributing to weight loss, but with appetite as the bigger lever.^[2] Evidence level: small human study.

Where the appetite effect actually comes from (preclinical)

Raising three monoamines is the trigger, but animal work has traced the appetite effect to more specific downstream pathways:

• Alpha-1 adrenoceptor and dopamine D1 pathways. In diet-induced obese rats, tesofensine's appetite suppression was driven largely by indirect stimulation of alpha-1 adrenoceptor and dopamine D1 receptor signaling downstream of the reuptake blockade — not by acting on those receptors directly.^[4]
• Restoring "reward" dopamine. Obesity is associated with blunted dopamine in reward-related brain regions. In obese rats, tesofensine reversed the reduced baseline dopamine in the nucleus accumbens and prefrontal cortex, normalizing forebrain dopamine while suppressing appetite and reducing weight — a proposed route to curbing reward-driven eating.^[5]
• Silencing a hunger-circuit switch. More recent work found tesofensine silences a specific subset of GABAergic neurons in the lateral hypothalamus (a hunger-regulating hub). Chemogenetically silencing those same neurons enhanced tesofensine's food-intake-suppressing effect, and the appetite effect was independent of taste aversion (meaning it did not simply make food unpleasant).^[6]

Pharmacokinetics: why it is a once-a-day pill

Tesofensine has a long half-life — it clears the body slowly — which supports once-daily oral dosing. This was characterized formally in a population pharmacokinetics study in Alzheimer's patients, where body weight influenced the volume of distribution (how widely the drug spreads through the body).^[7]

What we do NOT know

The specific brain-level details above are largely from rats, and animal mechanism does not guarantee the same magnitude of benefit — or the same safety margin — in people. There is no large human dose-response mechanistic dataset, and the long-term neurochemical effects of chronically raising three monoamines are not established.

How to read this section: for each area we give the plain-English claim, the proposed mechanism, the population actually studied, the observed effect, and the limitation. Tesofensine's evidence is stronger than most compounds discussed in peptide circles — it has real randomized human trials — but those trials are Phase 2 and relatively small.

Weight loss (the headline result)

Claim: tesofensine produces large weight loss for a single oral agent. Mechanism: appetite suppression plus a modest rise in energy expenditure. Population: the pivotal trial (Astrup et al., The Lancet 2008) randomized 203 obese adults (BMI 30–40) to placebo or one of three doses for 24 weeks, all on a modest diet. Effect: the numbers are best read as placebo-subtracted — that is, weight loss beyond the diet-plus-placebo group, which itself lost 2.0%. On top of that baseline, tesofensine added 4.5% at 0.25 mg, 9.2% at 0.5 mg, and 10.6% at 1.0 mg (all p<0.0001).^[1] In everyday terms, the total mean loss was roughly 6.5%, 11%, and 13% respectively — placing the 0.5 mg dose in the neighborhood of, though below, what modern GLP-1 drugs like semaglutide achieve. Limitation: single 24-week Phase 2 trial; no large, long-duration Phase 3 outcome data; efficacy beyond one year is uncharacterized.

Appetite suppression

Claim: markedly reduced hunger and food intake. Mechanism: serotonin-driven satiety plus dopamine reward modulation, downstream of monoamine reuptake blockade. Population: overweight/obese men in a controlled metabolic study. Effect: Sjödin and colleagues documented pronounced appetite suppression as the primary driver of weight loss.^[2] Limitation: small, short (two-week) mechanistic study at higher doses than the therapeutic range.

Increased energy expenditure (modest)

Claim: tesofensine slightly raises calorie burning, not just intake reduction. Mechanism: norepinephrine-driven sympathetic activation (thermogenesis). Population: the same metabolic study in overweight/obese men. Effect: a slight increase in nighttime energy expenditure, contributing alongside appetite suppression.^[2] Limitation: the thermogenic effect is secondary and modest; the appetite effect does most of the work. The same sympathetic activation is inseparable from the heart-rate signal covered under side effects.

Hypothalamic obesity (the Tesomet combination)

Claim: the tesofensine + metoprolol combination (Tesomet) can produce weight loss in a rare, hard-to-treat form of obesity. Mechanism: tesofensine drives weight loss; the beta-blocker metoprolol is added to blunt the cardiovascular effects. Population: a Phase 2 randomized trial in 21 adults with hypothalamic obesity (obesity caused by damage to the hypothalamus, e.g. after brain tumor treatment), over 24 weeks. Effect: Tesomet produced an additional mean weight reduction of 6.3% versus placebo (p=0.017), and 8 of 13 on the drug reached at least 5% loss versus 1 of 8 on placebo. Notably, the metoprolol component worked as intended — there was no significant change in heart rate or blood pressure.^[3] Limitation: very small trial in a specialized population; one participant discontinued for a serious anxiety exacerbation. This is the most advanced published obesity program for tesofensine — and it is Phase 2, not Phase 3.

The honest bottom line on "benefits"

• Real human efficacy exists — the 24-week weight loss in Astrup 2008 is genuine and substantial for a single agent.^[1]
• But it stops at Phase 2. There is no verified large Phase 3 obesity trial, and long-term efficacy and safety are unproven.
• The benefit and the risk share a source. The norepinephrine boost that helps burn calories is the same mechanism that raises heart rate.
• No regulator has approved it, so any use is off-label experimentation, not established medicine.

Read this first: the doses below come from published research, not from any approved label — because tesofensine is not approved. They are described for accuracy and harm-reduction context, not as medical guidance to self-administer an unapproved drug.

Doses used in trials

Tesofensine is an oral capsule taken once daily. Because it is a pill, there is no reconstitution or injection math — unlike the injectable peptides covered elsewhere on this site. The pivotal trial tested three fixed doses over 24 weeks.^[1]

Dose (once daily)	Placebo-subtracted weight loss (24 wks)	Approx. total mean loss	Heart-rate signal	Notes
0.25 mg	+4.5%	~6.5%	Smaller	Lower-end efficacy; gentler profile
0.5 mg	+9.2%	~11%	+7.4 bpm	Best efficacy-to-tolerability balance in Phase 2
1.0 mg	+10.6%	~13%	Larger	Maximum efficacy; more cardiovascular and psychiatric-type effects

The 0.5 mg dose is the most-cited research dose: it captures the large majority of the weight-loss effect seen at 1.0 mg while causing a smaller heart-rate rise. Moving from 0.5 mg to 1.0 mg buys relatively little extra weight loss (an additional ~1.4% placebo-subtracted) at the cost of more cardiovascular and psychiatric-type adverse events.^[1]

A worked example: reading the dose

Because doses are small (fractions of a milligram), it helps to think in micrograms. 0.5 mg = 500 mcg. If a capsule is labeled 250 mcg, a 0.5 mg daily dose is two capsules; a 1.0 mg dose (1,000 mcg) is four. The key practical point is that the therapeutic window is narrow — a "double dose" here is the difference between the balanced 0.5 mg and the higher-risk 1.0 mg, so casual dose-stacking is exactly the wrong instinct with this drug.

Timing (morning dosing matters)

Because tesofensine raises norepinephrine and dopamine — both alerting — it can disrupt sleep. Insomnia was among the common adverse events in the pivotal trial.^[1] That makes morning dosing the sensible default, taken consistently at the same time each day to keep blood levels steady given the drug's long half-life.^[7] Food is not a major factor in absorption, though taking it with breakfast may soften mild nausea.

The Tesomet approach (combination dosing)

The most advanced published program pairs 0.5 mg tesofensine with 50 mg metoprolol (a beta-blocker) specifically to offset the heart-rate rise — and in the hypothalamic-obesity trial it succeeded, showing no significant change in heart rate or blood pressure while preserving weight loss.^[3] This illustrates the central design problem with tesofensine: its efficacy and its cardiovascular signal come from the same norepinephrine mechanism, so serious development has centered on chemically counterbalancing that signal.

Duration

Published trials ran 24 weeks. There is no validated long-term protocol, no established cycling approach, and — as with essentially all weight-loss pharmacology — weight regain after stopping should be expected. Anything beyond the trial durations is uncharacterized.

None of the above should be read as a recommendation to self-administer an unapproved compound. It is a description of how the research doses were structured.

Straight talk: tesofensine's side-effect profile is well-characterized for a Phase 2 drug, and its defining safety issue is a rise in heart rate. This is not a fringe concern — it is the single reason the drug has struggled to advance toward approval.

The central safety signal: heart rate

In the pivotal trial, tesofensine increased heart rate by about 7.4 bpm at the 0.5 mg dose (p=0.0001), with larger increases at higher doses, plus increases in blood pressure and more psychiatric-type adverse events as the dose rose.^[1] This is a direct, predictable consequence of the norepinephrine (sympathetic) activation that also drives the drug's benefit — the two cannot be cleanly separated at the level of the core mechanism, which is why the Tesomet program bolted on a beta-blocker to blunt it.^[3]

Most common adverse events

In Astrup 2008, the most frequently reported side effects were:^[1]

Effect	Why it happens	Practical note
Dry mouth	Noradrenergic activity	Most commonly reported; hydrate, sugar-free gum, dental hygiene
Nausea	Central monoaminergic effect	Often eases after the first weeks; taking with food may help
Constipation / hard stools	Reduced gut motility	Fiber, fluids
Diarrhoea	GI monoaminergic effect (some patients)	Usually mild
Insomnia	Dopamine/norepinephrine alerting effect	Dose in the morning; avoid evening dosing
Elevated heart rate	Sympathetic activation	The primary safety concern; dose-dependent

Why the cardiovascular signal matters more than the number suggests

A mean rise of ~7 bpm can look modest on paper, but two things make it the crux of tesofensine's story. First, mean values hide outliers — some individuals respond with substantially larger increases. Second, the history of appetite-suppressant drugs that raise sympathetic tone is cautionary: sibutramine, a related weight-loss drug, was withdrawn from the U.S. and EU markets in 2010 after a large outcomes trial linked it to increased cardiovascular events in higher-risk patients. Regulators have judged tesofensine against that backdrop, which is a major reason no large cardiovascular-outcomes trial has cleared it for approval. The honest statement is that tesofensine's long-term cardiovascular safety in the general population is unknown, not reassuring-by-default.

Psychiatric and mood effects

Higher doses raised psychiatric-type adverse events in the pivotal trial.^[1] In the small Tesomet hypothalamic-obesity study, sleep disturbance (50% vs 13% on placebo), dry mouth (43% vs 0%), and headache were common, and one participant discontinued because of a serious anxiety exacerbation.^[3] Anyone with a significant anxiety, mood, or psychotic disorder should regard this drug with particular caution.

Interactions and populations to avoid (mechanism-based caution)

Because tesofensine raises serotonin, norepinephrine, and dopamine, its interaction profile mirrors that of other serotonergic/sympathomimetic drugs. These cautions follow directly from the mechanism; they are not drawn from tesofensine-specific interaction trials, which have not been published:

• MAOIs (e.g. phenelzine, selegiline): combining monoamine reuptake inhibition with MAO inhibition risks dangerous hypertension and serotonin syndrome — regarded as a hard "do not combine."
• SSRIs / SNRIs and other serotonergic drugs (triptans, tramadol, lithium, St. John's Wort): additive serotonin risk.
• Sympathomimetics and stimulants (pseudoephedrine, amphetamines, high-dose caffeine): additive heart-rate and blood-pressure effects.
• Pre-existing cardiovascular disease or uncontrolled hypertension: the added sympathetic load is a clear reason for avoidance.
• Pregnancy and breastfeeding: no safety data — avoid.

What to do if you experience side effects

• Palpitations, chest pain, fainting: seek emergency evaluation — do not "push through" cardiac symptoms.
• Sustained resting heart-rate or blood-pressure rise above your baseline: a reason to stop and reassess with a clinician.
• Signs of serotonin syndrome (agitation, high fever, sweating, tremor, rigidity, confusion): stop immediately and seek emergency care.
• Persistent insomnia: confirm the dose is taken in the morning; consider a lower dose.

For broader context, see Are Peptides Safe? and Peptide Side Effects.

Why this section matters: tesofensine is not an approved medicine, so any material sold is unregulated. That creates two separate problems — an identity/purity problem (is it really tesofensine, and how pure?) and a dosing-precision problem (with a narrow window between the balanced 0.5 mg and the higher-risk 1.0 mg, sloppy content uniformity is genuinely hazardous).

Legal and regulatory status (2026)

• Not FDA-approved for obesity or any other indication, and not approved by the EMA. It has never received marketing authorization in the US or EU.
• No verified Phase 3 obesity approval or result. The most advanced published obesity work is the Phase 2 Tesomet program (tesofensine + metoprolol).^[3] Claims of "approved in Mexico" or "completed Phase 3 trials" circulate widely online but are not supported by a primary source we could verify.
• Sold only as a research chemical in most markets, outside the regulated pharmacy supply chain.

What a credible product should show

• Third-party Certificate of Analysis (COA): independent HPLC purity testing plus mass-spectrometry identity confirming the compound is actually tesofensine.
• Batch-specific results: the COA should reference the exact lot you are buying, not a generic sample.
• Content uniformity: for a low-dose oral product, consistency of the labeled amount per capsule matters more than for most compounds, because the therapeutic window is narrow.

Red flags

• No COA, or a COA issued by the seller rather than an independent lab
• Prices far below the market, or vague labeling of the actual milligram content
• Explicit human-use or medical claims, which signal a non-compliant, higher-risk vendor
• Any suggestion that heart-rate monitoring is unnecessary

For the complete legal picture, read Are Peptides Legal?

Tesofensine is usually weighed against the modern GLP-1 and multi-receptor agonists that now dominate obesity treatment. None of these comparisons rest on head-to-head human trials — they contrast mechanisms, approval status, and the size of each drug's own trial results.

Tesofensine vs. GLP-1 drugs (semaglutide, tirzepatide)

Factor	Tesofensine	Semaglutide / Tirzepatide
Class	Triple monoamine reuptake inhibitor (brain chemistry)	GLP-1 (and GIP) receptor agonists (gut hormones)
Route	Oral, once daily	Primarily injectable (weekly); some oral
Approval	Not approved anywhere	FDA-approved for weight management
Trial weight loss	~11% total at 0.5 mg (Phase 2, 24 wks)	~15% (semaglutide) to ~20%+ (tirzepatide) in Phase 3
Main safety signal	Elevated heart rate	GI effects (nausea, vomiting)

The practical summary: the GLP-1 class now delivers larger, better-validated weight loss with regulatory approval behind it, which is why tesofensine remains a research curiosity rather than a mainstream option. Newer triple-hormone agonists like retatrutide are pushing efficacy even higher.

Tesofensine vs. phentermine

Both raise norepinephrine and dopamine, and both suppress appetite through sympathetic activation — so both share the heart-rate caveat. Tesofensine adds serotonin reuptake inhibition and has a longer duration of action (once-daily dosing), and produced larger weight loss in trials than phentermine typically does. Phentermine, however, is an approved (short-term) drug in the US, whereas tesofensine is not.

Quick answer: because tesofensine is sold only as an unregulated research chemical, pricing varies widely and is not standardized the way an approved prescription is. Expect meaningful variation between vendors, and treat unusually cheap material as a warning sign rather than a bargain.

The more important cost is the hidden one: with a narrow dose window and a real cardiovascular signal, buying material with an unverified milligram content or no independent COA is the expensive mistake. Content-accuracy and third-party testing should outrank price in any sourcing decision. For an approved, quality-controlled alternative in the same goal category, the GLP-1 drugs — though more expensive per month — come with regulatory oversight that a research chemical does not.